Poxel Announces New Strategic Direction with Increasing Focus on Rare Metabolic Diseases Following Recent Achievements

Poxel Announces New Strategic Direction with Increasing Focus on Rare Metabolic Diseases Following Recent Achievements Following the recent approval of TWYMEEG® (Imeglimin) in Japan and associated potential future revenues, Poxel to…